STATE OF NEW YORK

705--B

2021-2022 Regular Sessions

IN ASSEMBLY

(Prefiled)

January 6, 2021

Introduced by M. of A. L. ROSENTHAL -- read once and referred to the Committee on Alcoholism and Drug Abuse -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- reported and referred to the Committee on Ways and Means -- recommitted to the Committee on Ways and Means in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the mental hygiene law, in relation to the availability of buprenorphine in opioid treatment programs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The mental hygiene law is amended by adding a new section 32.12 to read as follows:

§ 32.12 Availability of buprenorphine.

Every facility licensed or authorized to provide services for substance use disorders related to opioids that employs a qualified practitioner, as determined by federal law, shall ensure at least one practitioner in the facility has received an appropriate waiver and/or has completed required training to administer or prescribe buprenorphine to individuals in their care with a substance use disorder where such drug is determined appropriate for their treatment.

§ 2. This act shall take effect on the one hundred twentieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

EXPLANATION--Matter in *italics* (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD00547-06-2